AMNOG ResultsDeutsch

Chemical subgroup

L01FF – PD-1/PD-L1 (Programmed Cell Death-1-Rezeptor/Programmed Cell Death-Ligand-1)-Inhibitoren

  • Anatomical main group L: ANTINEOPLASTISCHE UND IMMUNMODULIERENDE MITTEL
  • Therapeutic subgroup L01: ANTINEOPLASTISCHE MITTEL
  • Pharmacological subgroup L01F: MONOKLONALE ANTIKÖRPER UND ANTIKÖRPER-WIRKSTOFF-KONJUGATE

The interface is translated. The G-BA decision texts are only available in German.

115Decisions
171Patient groups

Added benefit by patient group

  • Major1
  • Considerable36
  • Minor17
  • Non-quantifiable12
  • Not proven104
  • Lesser benefit1

Decisions, newest first

ATC group names are the official German titles of ATC-GM, version 2026.

Das Wissenschaftliche Institut der AOK (WIdO) ist Urheber der ATC-GM mit DDD, die auf dem vom WHO Collaborating Centre for Drug Statistics Methodology herausgegebenen Werk mit dem Titel „ATC Index with DDDs and Guidelines for ATC Classification and DDD Assignment“ beruht. Die amtliche Veröffentlichung erfolgt durch das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).

In English: The Scientific Institute of the AOK (WIdO) is the author of ATC-GM with DDD, which is based on the work “ATC Index with DDDs and Guidelines for ATC Classification and DDD Assignment” published by the WHO Collaborating Centre for Drug Statistics Methodology. The official publication is by the Federal Institute for Drugs and Medical Devices (BfArM).

Data status: 2026-10-29